Marco Mancini

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin

Ramiro Garzon, Michela Garofalo, Maria Paola Martelli et al. · Proceedings of the National Academy of Sciences · 2008 · 496 citations · Full text

Engineering, Mixed-phenotype Acute Leukemia, Genetics +18

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · The Lancet · 2008 · 482 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +9

Epigenetic Silencing of the Myelopoiesis Regulator microRNA-223 by the AML1/ETO Oncoprotein

Francesco Fazi, Serena Racanicchi, Giuseppe Zardo et al. · Cancer Cell · 2007 · 384 citations · Full text

Epigenetic Silencing, Chromatin, Myelopoiesis Regulator Microrna-223 +12

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

Sergio Amadori, Stefan Suciu, Dominik Selleslag et al. · Journal of Clinical Oncology · 2016 · 341 citations · Full text

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 253 citations